PMP22 and peripheral neuropathy: Despite the potential of PXT3003 (a combination of baclofen, naltrexone, and sorbitol), in which the therapeutic effect is related to downregulation of PMP22, an effect that is similarly observed when PMP22-specific small interfering ribonucleic acid formulations are used [1], we believe our novel NanoCur treatment may have a broader mechanism of action, which might be beneficial to several peripheral neuropathies in addition to CMT1A.